Scholarlink

Introduction <p>Noncommunicable diseases, primarily cardiovascular diseases (CVDs), are an emerging cause of morbidity in sub-Saharan Africa. Dyslipidaemia, a key modifiable CVD risk factor, is increasing but remains underdiagnosed and undertreated, particularly among people living with HIV (PLHIV), where HIV-related chronic inflammation, antiretroviral therapy (ART), and sociodemographic factors may contribute. This study assessed the prevalence, correlates of dyslipidaemia, and estimated 10-year CVD risk among PLHIV and people without HIV (PWoH) adults in Rwanda.</p> Methods <p>We analysed baseline data from 1,546 adults (1,234 PLHIV and 312 PWoH) enrolled in the NCOHIRWA Cohort from 12 Rwandan health facilities. Data were collected via standardised World Health Organisation (STEP) questionnaires. Dyslipidaemia was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria, and 10-year CVD risk was calculated via the Framingham risk score. For group comparisons, chi-square tests were used. Multivariate logistic regression identified independent predictors of dyslipidaemia, with adjusted odds ratios and 95% confidence intervals reported.</p> Results <p>Overall, 979 participants (61.9%) had dyslipidaemia, with comparable prevalence rates among PLHIV (744/1234; 60.29%) and PWoH participants (205/312; 65.06%). The PWoH participants had higher LDL-C levels (59 (18.9%) vs. 120 (9.7%), p &lt; 0.0001). Independent predictors of dyslipidaemia included female sex, older age, obesity, and widowhood. PLHIV had lower odds of having elevated total cholesterol (aOR = 0.68, 0.49–0.95). Based on the estimated 10-year CVD risk, 3.95% of the participants had high and 21.47% had very high 10-year CVD, respectively, which was concentrated among older, widowed women with low education levels.</p> Conclusion <p>Dyslipidaemia and elevated CVD risk are highly prevalent among the study participants, with disparities based on HIV status, sex, and social vulnerability. Routine lipid screening and integrated HIV-CVD care, particularly for high-risk subgroups such as older women, are essential for reducing the long-term CVD burden.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence, correlates of dyslipidaemia, and 10-year cardiovascular risk among people living with HIV and people without HIV adults in Rwanda: insights from the NCOHIRWA cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月10日

查看全文
  • Valentine Dushimiyimana,
  • Yves Marie Ishimwe Kirunga,
  • Albert Tuyishime,
  • Simeon Tuyishime,
  • K. M. Monirul Islam,
  • Ladislas Nshimiyimana,
  • Vivianne Umuhire Niyonkuru,
  • Noel Gahamanyi,
  • Christian Nsanzabaganwa,
  • Pacifique Mukashema,
  • Jude Kong,
  • Madeleine Durand,
  • Ntobeko A. B. Ntusi,
  • Marc Twagirumukiza,
  • Brenda Asiimwe Kateera,
  • Sabin Nsanzimana,
  • Steven Callens,
  • Pacifique Ndishimye,
  • Gallican Nshogoza Rwibasira,
  • Francois Uwinkindi,
  • Eric Remera,
  • Jean Claude Semuto Ngabonziza,
  • Clarisse Musanabaganwa,
  • Claude Mambo Muvunyi,
  • Ferdinand Nasibu,
  • Leopold Bitunguhari,
  • Deo Mutambuka,
  • Jean Berchmans Tugirimana,
  • Alphonse Mbarushimana

摘要

Introduction

Noncommunicable diseases, primarily cardiovascular diseases (CVDs), are an emerging cause of morbidity in sub-Saharan Africa. Dyslipidaemia, a key modifiable CVD risk factor, is increasing but remains underdiagnosed and undertreated, particularly among people living with HIV (PLHIV), where HIV-related chronic inflammation, antiretroviral therapy (ART), and sociodemographic factors may contribute. This study assessed the prevalence, correlates of dyslipidaemia, and estimated 10-year CVD risk among PLHIV and people without HIV (PWoH) adults in Rwanda.

Methods

We analysed baseline data from 1,546 adults (1,234 PLHIV and 312 PWoH) enrolled in the NCOHIRWA Cohort from 12 Rwandan health facilities. Data were collected via standardised World Health Organisation (STEP) questionnaires. Dyslipidaemia was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria, and 10-year CVD risk was calculated via the Framingham risk score. For group comparisons, chi-square tests were used. Multivariate logistic regression identified independent predictors of dyslipidaemia, with adjusted odds ratios and 95% confidence intervals reported.

Results

Overall, 979 participants (61.9%) had dyslipidaemia, with comparable prevalence rates among PLHIV (744/1234; 60.29%) and PWoH participants (205/312; 65.06%). The PWoH participants had higher LDL-C levels (59 (18.9%) vs. 120 (9.7%), p < 0.0001). Independent predictors of dyslipidaemia included female sex, older age, obesity, and widowhood. PLHIV had lower odds of having elevated total cholesterol (aOR = 0.68, 0.49–0.95). Based on the estimated 10-year CVD risk, 3.95% of the participants had high and 21.47% had very high 10-year CVD, respectively, which was concentrated among older, widowed women with low education levels.

Conclusion

Dyslipidaemia and elevated CVD risk are highly prevalent among the study participants, with disparities based on HIV status, sex, and social vulnerability. Routine lipid screening and integrated HIV-CVD care, particularly for high-risk subgroups such as older women, are essential for reducing the long-term CVD burden.